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QUESTION ASKED: For the population of women with gynecologic (uterine, cervical, ovarian,
and vulvar) cancers whowere covered byMedicaid during their treatment (in North Carolina from
2003-2008), what is the benefit of enrollment in Medicaid before versus after cancer diagnosis?
SUMMARY ANSWER: Lack of enrollment in Medicaid before diagnosis was statistically
associated with advanced stage at diagnosis in women with gynecologic cancers, and this effect
was greatest in uterine cancers.
WHAT WE DID: Using the North Carolina Central Cancer Registry linked with Medicare,
Medicaid, and private insurance billing claims, we identified a cohort of 782women diagnosedwith
gynecologic cancers, from 2003 to 2008, who had exclusive Medicaid coverage during the study
window. They were grouped by timing of enrollment: those with and without pre-diagnosis
enrollment within 6months before diagnosis. Due to baseline differences between these groups, we
used propensity matching to balance on age, race, geography, cancer site, stage at diagnosis, and
presence of any other cancer diagnosis. Stage at diagnosis was evaluated using logistic regression,
and all-cause mortality was assessed with Cox proportional hazard models.
WHATWE FOUND: Lack of enrollment in Medicaid before diagnosis was statistically associated
with advanced stage at diagnosis in women with gynecologic cancers (OR, 1.46; 95% CI, 1.03 to
2.05) in a propensity-matched cohort (Fig). When stratified by cancer site, this difference was
greatest in uterine cancers (OR, 1.74; 95% CI, 0.87 to 3.47). In assessing survival, lack of pre-
diagnosis Medicaid coverage had a mortality hazard ratio of 1.19 (95% CI, 0.92 to 1.53), P = 0.06.
BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: It is important to note that the limitations
of our data set do not allow us to be certain that women who lacked Medicaid before enrollment
were also ineligible. It is likely that some women in this group were financially eligible, but simply
not enrolled due to barriers of knowledge, literacy, or the willingness to engage with the health care
system. Therefore, efforts to not only expand Medicaid, but also promote ease of enrollment,
through public health outreach, are also important to address disparities in gynecologic cancer
detection and ultimate outcomes. Also, we did not control for comorbidities because this
information cannot be elicited for patients with non-continuous or interrupted insurance
enrollment, as was the case in this data set. Finally, due to our propensity matching, including
matching of stage, we likely under-report survival differences between the two groups. Stage
is the primary driver of survival, and before matching, stage at diagnosis differed substantially
between the enrollment groups.
REAL-LIFE IMPLICATIONS: Given the existence of a cervical cancer screening program inNorth
Carolina and lack of Medicaid expansion, these data suggest that screening programs alone are not
sufficient to counteract the delay in diagnosis that is common for the uninsured.
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FIG.Mortality after gynecologic cancer diagnosis in women younger than 65 years by timing of Medicaid enrollment in North Carolina (2003 to 2008): overall
study cohort. Kaplan-Meier survival curves stratified by prediagnosis Medicaid enrollment during the study period. Mortality is measured since month of
diagnosis until death or censoring.
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Abstract
Purpose
Many low-income patients enroll in Medicaid at the time of cancer diagnosis, which
improves survival outcomes. Medicaid enrollment before cancer diagnosis may confer
additional benefits. Our objective was to compare stage at diagnosis and overall mortality
between women with and without Medicaid enrollment before gynecologic cancer
diagnosis.
Methods and Materials
Women younger than 65 years with a gynecologic cancer (2003 to 2008) were identified
through the North Carolina Central Cancer Registry and linked to state Medicaid
enrollment files. Those with and without Medicaid enrollment within 6 months before
diagnosis were identified. Propensity matching was used to balance the exposure groups.
Stage at diagnosis was evaluated by using logistic regression, and all-cause mortality was
assessed with Cox proportional hazard models.
Results
Of 564 women, one half (n = 282) had prediagnosis Medicaid enrollment. Disease
sites included the cervix (44%), uterus (25%), ovary (26%), and vulva/vagina (5%). More
than one half (51%) of cancers were advanced stage. Women without prediagnosis
Medicaid had an increased odds of advanced-stage disease (hazard ratio, 1.46; 95% CI,
1.03 to2.05).Crudesurvival outcomesdifferedsignificantlybetween thegroups;however,
when adjusted for stage at diagnosis, lack of prediagnosis Medicaid coverage had a
hazard ratio of 1.19 (95% CI, 0.92 to 1.53).
Conclusion
Medicaid enrollment before gynecologic cancer diagnosis is associated with an earlier
stage at presentation. Given the existence of a cervical cancer screening program inNorth
Carolinaand lackofMedicaidexpansion, thesedata suggest that screeningprogramsalone
are not sufficient to counteract the delay in diagnosis that is common for uninsured
individuals.
INTRODUCTION
Health insurance coverage, including Med-
icaid, is associated with increased access to
care and improved health outcomes.1 Med-
icaid is a socialwelfare program in theUnited
States that offers health and medical services
to low-income families and individuals,
providing coverage to patients who cannot
afford private insurance.2 The expansion of
Medicaid has been shown to increase use of
preventive services, improve access to pri-
mary care, and decrease mortality among
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new enrollees.3,4 Research has found that having health insur-
ance after a cancer diagnosis improves outcomes,5 but currently
unknown is whether prediagnosis coverage yields additional
benefits.
Gynecologic cancers encompass screen-detectable (cer-
vical), early-detectable (uterine, vulvar/vaginal), and poorly
detectable (ovarian) disease. Cervical cancer is readily di-
agnosable in early microscopic disease stage screening with
Pap or human papillomavirus testing. Uterine and vulvar
cancer detection is based on evaluation after patients disclose
symptoms, such as postmenopausal bleedingor vulvar pain, to
medical providers. Ovarian cancer is poorly detected, with the
majority of patients not experiencing symptoms that would
lead to diagnosis until the disease has reached advanced
stages. Gynecologic cancers have heterogeneous disease
presentations as well as the common treatment point of the
gynecologic oncologist; thus, this provides a unique oppor-
tunity to study the impact of the timing of obtainingMedicaid
coverage on patient outcomes across a spectrum of cancer
contexts.
In North Carolina, income limits for Medicaid eligibility
rank in the bottomquartile of all US states, and adults younger
than 65 years without children or disabilities are currently
ineligible for coverage.6 For those who do not initially meet
income requirements forMedicaid, the acute financial burden
of a cancer diagnosismay decrease their income sufficiently to
qualify for Medicaid enrollment. Among patients who have
Medicaid coverage after a diagnosis of cancer, it is unknown
whether their clinical outcomes would be different according
to their prediagnosis Medicaid enrollment status. To in-
vestigate the impact of timing of Medicaid enrollment on
cancer outcomes, we conducted a population-based retro-
spective cohort study that identified women younger than
65 years with gynecologic cancer enrolled in Medicaid in
North Carolina (between 2003 and 2008) and compared
outcomes (to the end of 2010) among those with and without
prediagnosis Medicaid enrollment.
METHODS AND MATERIALS
Data Source and Study Population
This study was approved by the University of North Carolina
Institutional Review Board (Study # 13-2863). The North
Carolina Central Cancer Registry (NCCCR) was used to
identify all women with a gynecologic cancer from 2003 to
2008. Women with benign or in situ histology (including
low-malignant-potential tumors) diagnosed at death or
postmortem were excluded by using NCCCR flags and In-
ternational Classification of Diseases for Oncology, Third
Edition, codes (Appendix Table A1, online only). The North
Carolina Integrated Cancer Information and Surveillance
System links identified cancer cases from the NCCCR with
administrative data from Medicare, Medicaid, and benefi-
ciaries in privately insured health plans across the entire state.7
The current study population was derived by using these
Integrated Cancer Information and Surveillance System
linkages and was restricted to women younger than 65 years
who received a diagnosis between July 1, 2003, and December
31, 2008, and with linked enrollment in state Medicaid files
during the study period. We restricted the cohort to those
younger than 65 years because of near-universal Medicare
enrollment starting at age 65 years.
For the purposes of this study, we defined prediagnosis
Medicaid enrollment as at least 1month ofMedicaid coverage
during the 6months before cancer diagnosis. Patients who did
not fulfill this criterion were considered not to have been
covered prediagnosis. All patients with any enrollment in
privately insured health plans or inMedicare before diagnosis
were excluded from further analysis. Within the Medicaid
cohort, women enrolled due to primary disability, as cate-
gorized in the state enrollment files, were excluded because
they represent an unhealthy subgroup with excess mortality
risk compared with the general population.Womenwhowere
not enrolled for at least 1 month before death were also ex-
cluded. Given the small number in the other (nonwhite,
nonblack) race category, these patients were excluded as well.
Outcome Variables and Covariates
The two outcomes assessed were cancer stage at diagnosis and
all-cause mortality, both reported by the NCCCR. Stage at
diagnosis is reported in the summary staging variable, which is
consistently reported by all state andnational cancer registries.
For our study, stage as an outcome was defined in a binary
fashion: early stage (local) and advanced stage (regional and
distant).Mortality was updated annually by the registry and at
the time of study analysis, was available throughDecember 31,
2010.
Age, race, population density of patient’s county of resi-
dence (metropolitan, nonmetropolitan), cancer site (cervix,
uterus, ovary, vulva/vagina), and multiple cancer diagnoses
(yes or no for any other cancer), were included as covariates
for propensity matching. Multiple cancer diagnosis refers to
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whether the gynecologic cancer diagnosis of interest was the
patient’s first andonly cancer diagnosis.Age at diagnosis, race,
and multiple cancer diagnoses (yes, no) were obtained from
NCCCRdata.7Rural/urban classificationwasderived fromUS
Department of Agriculture data and was dichotomized at the
county level intometropolitan versus nonmetropolitan on the
basis of the USOffice ofManagement and Budget rural-urban
continuum codes.8 Cancer site was defined according to the
International Classification of Diseases for Oncology, Third
Edition, cancer site codes (Appendix Table A1).
Statistical Analysis
After the aforementioned exclusions were applied, propensity
matching was performed to balance the cohort on demo-
graphic and clinical covariates. Logistic regressionwas used to
estimate the probability of no Medicaid enrollment before
diagnosis. Standardized differences were calculated and were
all under 0.1, which indicates appropriatematching. Stage was
not included in thismatching becausewe considered stage as a
mediator in the relationship between Medicaid enrollment
timing and outcomes. Groupings of , 10 in covariate cate-
gories were suppressed as required in the data use agreement
with the payer data sources.
Univariable and bivariable analyses of enrollment groups
(prediagnosis Medicaid enrollment versus no enrollment),
covariates, and the outcomes of stage at diagnosis and mor-
tality were performed before and after propensity matching.
Student t test and the x2 statistic were used to assess the
relationship between independent variables and outcome
variables. Binary logistic regression was used to generate odds
ratios of the likelihood of early versus advanced stage at the
time of diagnosis. Unadjusted Kaplan-Meier survival plots
were generated, with stratification for cancer site. We con-
structed Cox proportional hazard models, both with and
without cancer stage, to generate hazard ratios (HRs) for time
to death. Statistical significance was set at P, .05. All analyses
were performed with SAS 9.3 software (SAS Institute, Cary,
NC).
RESULTS
Descriptive
A total of 13,845 unique cases of gynecologic cancer during
2003 to 2008 were identified from the NCCCR (Appendix Fig
A1). After applying tumor-level and demographic exclusions,
12,791 cases of uterine, ovarian, cervical, and vulvar/vaginal
cancer remained. Patients who did not have Medicaid
(n = 5,571) or those whose primary eligibility was based on
disability (n=141)were excluded.After additional payer-level
exclusions, the cohort comprised 782 women with gyneco-
logic cancerwhowere enrolled exclusively inMedicaid. Before
matching, the group with prediagnosis Medicaid enrollment
had a larger proportion of black women than the group
without prediagnosis enrollment (44% v 32%, respectively,
P , .001). Disease site distribution also varied significantly
between groups: uterine cancer represented a greater pro-
portionof cancer inwomenwithprediagnosis coverage (34% v
23%, respectively, P, .001), whereas ovarian cancer was less
common (17% v 28%, respectively, P , .001; Table 1). Age,
populationdensity of county of residence, andmultiple cancer
diagnoses did not differ between study groups.
After propensity matching, the cohorts were balanced on
race, cancer site, age, population density, and multiple cancer
diagnoses (Table 1). There was a total of 564 women with a
median follow-up timeof 22months. Themean age of the final
study cohort was 46 years, with a racial breakdown of 65%
(n = 369) white and 35% (n = 195) black. One half (51%) of
the cohort had advanced-stage disease (regional or distant) at
presentation, and 177 (31%) died by the end of the follow-up
period. The largest cancer group was cervical (44%), followed
by uterine (26%), ovarian (25%), and vulvar/vaginal (6%).
Medicaid Enrollment Timing and Stage at Diagnosis
Logistic regression models revealed a significantly increased
probability of advanced stage at diagnosis in women without
prediagnosis Medicaid enrollment (OR, 1.46; 95% CI, 1.03 to
2.05; Table 2). When stratified by cancer site, this difference
was greatest in uterine cancer (OR, 1.74; 95%CI, 0.87 to 3.47).
However, there was considerable loss in power and impre-
cision in estimates as a result of small sample sizes once
stratified (Table 2).
Medicaid Enrollment Timing and Mortality
Womenwithout prediagnosisMedicaid coverage had a higher
mortality rate after diagnosis than those with prediagnosis
coverage (Fig 1). This was driven primarily by the disparate
survival outcomes in patients with cervical and uterine cancer
(Fig 2). Table A2 shows the step-wise Cox proportional
hazard models of mortality. In model 1, which compared the
propensity-matched cohorts, lack of prediagnosis Medicaid
coverage had a mortality HR of 1.28 (95% CI, 0.99 to 1.65;
P = .06). When stage, which we consider a mediator, was
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included inmodel 2, themortality relationshipwas attenuated
(HR, 1.19; 95%CI, 0.92 to 1.53). Advanced stage of diseasewas
the primary driver of mortality risk (regional stage HR, 3.45;
distant stage HR, 10.02) versus local cancer.
DISCUSSION
For low-income women with gynecologic cancer in North
Carolina between 2003 and 2008, Medicaid coverage before
diagnosis was significantly associated with earlier stage at di-
agnosis. Many gynecologic cancers are curable with standard
treatment when diagnosed at early stages.9 The current results
suggest that lack of prediagnosis Medicaid coverage can be an
important driver of disparities in low-income populations. We
used propensitymatching to balance the study groups; however,
beforematching, stage at diagnosiswas significantly higher in the
women without prediagnosis coverage. Because stage is such a
strong driver of mortality, we likely underreported the survival
benefits of prediagnosis Medicaid coverage.
Cervical, uterine, and vulvar/vaginal cancers can be readily
detected early through either screening (cervical) or reports of
early symptoms to health care providers (uterine, vulvar/
vaginal). Immediate access to primary care services may
trigger the appropriate medical investigations that lead to
timely diagnosis and treatment at early stages and, thus, im-
proved survival. Conversely, lack of access to screening and
detection services may delay diagnosis. The current findings
are consistent with contemporary sociobehavioral theory,
whichholds that therelative impactof socioeconomicstatuson
disease mortality depends on overall treatability of a given
disease.10-12 Thus, in this scenario, women with cervical,
uterine, and vulvar/vaginal cancerswill bemost affected by the
lack of prediagnosis Medicaid coverage.
In North Carolina, a stand-alone cervical cancer screening
program is available to women regardless of insurance cov-
erage.13 Cancer-specific screening programs that are in-
dependent of broader health care coverage programs can
Table 1. Study Population: Medicaid Enrollees With Gynecologic Cancer in North Carolina, 2003 to 2008
Prediagnosis Medicaid Enrollment: Original,
No. (%)
Prediagnosis Medicaid Enrollment: Propensity
Matched, No. (%)
Characteristic Total (n = 782) No (n = 302) Yes (n = 480) P Total (n = 564) No (n = 282) Yes (n = 282) P
Mean age (SD), years 46.1 (11.5) 46.2 (10.8) 46.1 (11.9) .90 45.9 (11.3) 45.8 (10.9) 46.0 (11.8) .83
Race
White 471 (60) 204 (68) 267 (56) 369 (65) 185 (66) 184 (65)
Black 311 (40) 98 (32) 213 (44) , .001 195 (35) 97 (34) 98 (35) .93
Population density of county
of residence*
Metropolitan 483 (62) 183 (61) 300 (63) 344 (61) 175 (62) 169 (6)
Nonmetropolitan # 300 (# 40) 118 (39) 180 (38) .63 220 (39) 107 (38) 113 (40)
Stage
Missing * 0 (0) .60
Local 364 (47) 110 (36%) 254 (53) 238 (42) 107 (38) 131 (46)
Regional 208 (27) 94 (31%) 114 (24) 158 (28) 80 (28) 69 (24)
Distant 186 (24) $ 90 ($ 30) $ 90 ($ 20) 153 (27) $ 70 ($ 25) $ 65 ($ 23)
Unknown 24 (3) * * , .001 15 (3) * * .12
Cancer site
Cervix 329 (42) 131 (43) 198 (41) 246 (44) 122 (43) 124 (44)
Uterus 234 (30) 69 (23) 165 (34) 140 (25) 69 (24) 71 (25)
Ovary 167 (21) 84 (28) 83 (17) 147 (26) 73 (26) 74 (26)
Vulva/vagina 52 (7) 18 (6) 34 (7) , .001 31 (5) 18 (6) 13 (5) .84
Multiple cancer diagnoses
No 700 (90) 269 (89) 431 (90) 505 (90) 253 (90) 252 (89)
Yes 82 (10) 33 (11) 49 (10) .75 59 (10) 29 (10) 30 (11) .89
*Cell size , 10 suppressed in compliance with data use agreements.
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potentially mitigate income-based disparities in cancer sur-
vival. Although these programs are helpful, the current results
demonstrate that they are not sufficient in providing early
access to care for the spectrum of gynecologic cancers
amenable to early diagnosis and cure, which explains the
findings with regard to cervical and uterine cancer.
Uterine cancer, which is more than four times more
common than cervical cancer,14 can also be detected early,15
but this detection depends on physical examination and
evaluation rather than on screening. Therefore, one would
expect Medicaid enrollment to have a greater impact on
uterine cancer outcomes than cervical cancer outcomes,
where screening availability outside Medicaid enrollment
exists and which was the case in the current study. Uterine
cancer disproportionately affects minority populations, with
an increased incidence among black women,16,17 and in
low-income populations, it is commonly associated with
advanced-stage disease at presentation.18 These populations
are especially vulnerable to adverse outcomes from this
disease and may benefit from insurance coverage that allows
for comprehensive examinations.
Prior researchhas found thatMedicaid coverage at the time
of cancer diagnosis confers survival benefits.5 The implication
of this work is that access to care before diagnosis is the driver
of these benefits. The current results support this assumption
by demonstrating that enrollment in Medicaid before di-
agnosis is associated with early-stage cancer diagnosis. This
was recently reinforced by an analysis of patients with cervical
cancer in theNational CancerDatabase.19 By comparing years
before and after the implementation of the Affordable Care
Act, the study authors foundan increase of 9 percentage points
in women who presented with early-stage disease. The Af-
fordable Care Act aims to increase the number of patients
covered byMedicaid by expanding enrollment eligibility to all
citizens whose annual income is up to 138% of the federal
poverty level. In states without Medicaid expansion, however,
those with incomes , 138% of the federal poverty level will
not qualify for discounted insurance plans and are not eligible
for Medicaid without coexisting disabling conditions. North
Carolinahas optedout ofMedicaid expansion and thushas left
approximately 357,000 uninsured people per year who do not
qualify for Medicaid and discounted insurance; of these, 47%
arewomen and 62% are fromworking families.20,21 As a safety
net, Medicaid enrollment could become available to patients
who find themselves in this coverage gap only after a cancer
diagnosis causes financial hardship and their lower (family)
income subsequently makes them eligible to enroll in Med-
icaid. The current data suggest, however, that this approach is
inadequate and continues to perpetuate disparities in gyne-
cologic cancer outcomes.
Limitations of our data set do not allow for certainty that
women who lacked Medicaid before enrollment were also in-
eligible. Some women in this group were likely financially eli-
gible but simply not enrolled due to barriers of knowledge,
literacy, or willingness to engage with the health care system.
Therefore, efforts not only to expand Medicaid but also to
0
0.2
0.4
0.6
0.8
1.0
20 40 60 80 100
Log-rank P = .0534
Su
rv
iv
al
 (p
ro
ba
bi
lit
y)
Survival Duration Since Diagnosis (months)
Prediagnosis Medicaid enrollment
No Yes
FIG 1.Mortality after gynecologic cancer diagnosis in women younger than
65 years by timing of Medicaid enrollment in North Carolina (2003 to 2008):
overall study cohort. Kaplan-Meier survival curves stratified by prediagnosis
Medicaid enrollment during the study period. Mortality is measured since
month of diagnosis until death or censoring.
Table 2. Prediagnosis Medicaid Enrollment and the Odds of
Advanced-Stage Disease at Presentation of Gynecologic
Cancer Overall and by Specific Cancer Site From 2003 to
2008
Cancer Site
Prediagnosis
Medicaid
Enrollment Odds Ratio 95% CI
All gynecologic cancer
sites (n = 564)*
No 1.46 1.03 to 2.05
Individual cancer site*
Cervix No 1.50 0.91 to 2.49
Uterus No 1.74 0.87 to 3.47
Ovary No 1.41 0.63 to 3.11
Vulva/vagina No 1.00 0.23 to 4.31
*Number of deaths in each group: all sites (n =177), cervix (n =76), uterus (n =
41), ovary (n = 55), vulva/vagina (n = 5).
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promote ease of enrollment through public health outreach are
important to addressing disparities in gynecologic cancer de-
tection and ultimately outcomes.
The current study has several other limitations, many of
which are consistent with registry-linked claims data.22 First,
we were unable to measure person-level indicators of so-
cioeconomic status as a covariate; however, all patients in-
cluded in the analysis were poor based onMedicaid eligibility
income requirements at# 250% of the federal poverty level.
Second, we did not control for comorbidities because this
information cannot be elicited for patients with non-
continuous or interrupted insurance enrollment, as was the
case in this data set. Third, wewere limited to a singleUS state,
so the results may not be generalizable nationwide, although
rates of gynecologic cancer in North Carolina are similar to
that in SEER reports.2 Fourth, we were limited to all-cause
mortality; therefore, the observed disparate survival outcomes
could possibly be due to noncancer-related deaths, but this
seems unlikely because of the association between stage of
cancer and mortality observed in this population. Moreover,
even a noncancer-related mortality disparity would suggest
benefits of more comprehensive insurance coverage. Fifth,
because the data were derived on the basis of insurance en-
rollment, we were unable to include data from patients who
never had any insurance coverage during the study period,
which is a research question that was beyond the scope of this
study. Finally, because of our propensity matching, including
matching of stage, we likely underreport survival differences
between the two enrollment groups. Stage is the primary
driver of survival, and before matching, stage at diagnosis
differed substantially between enrollment groups.
The state of North Carolina currently is considering ex-
pansion of its Medicaid program. Evidence suggests that such
an expansion is associated with mortality benefits across
B
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FIG 2. (A-D) Mortality after gynecologic cancer diagnosis in women younger than 65 years by timing of Medicaid enrollment in North Carolina (2003 to 2008)
according to specific cancer site. Kaplan-Meier survival curves stratified by prediagnosis Medicaid enrollment during the study period grouped by International
Classification of Diseases for Oncology, Third Edition, cancer site codes in the North Carolina Central Cancer Registry.
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populations regardless of diagnosis.4 This study adds to that
evidence by finding that in vulnerable populations, provision
of insurance coverage at the time of cancer diagnosis is not
sufficient to counteract the adverse impact of lack of prior
insurance coverage. Although stand-alone cancer-specific
screening programs likely improve outcomes, they cannot
replace the benefits of more comprehensive medical evalu-
ations that can detect curable cancers at an early stage.
Acknowledgment
Supported by the National Cancer Institute of the National Institutes of Health
under award number R25CA116339 and the North Carolina University
CancerResearchFund.The funding sourceshadno role in thedesignandconduct
of the study; collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to submit
the manuscript for publication. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National
Institutes of Health.
Presentedat theAnnualMeeting onWomen’sCancer, Chicago, IL,March28-31,
2015.
We acknowledge and thank Dominik Wolf, medical editor, for his contributions.
Authors’ Disclosures of Potential Conflicts of Interest
Disclosures provided by the authors are available with this article at
jop.ascopubs.org.
Author Contributions
Conception and design:KemiM.Doll, EthanM. Basch, Anne-MarieMeyer
Collection and assembly of data: Kemi M. Doll, Ke Meng, Anne-Marie
Meyer
Dataanalysisand interpretation:KemiM.Doll, KeMeng,EmmaL.Barber,
Paola A. Gehrig, Wendy R. Brewster, Anne-Marie Meyer
Manuscript writing: All authors
Final approval of manuscript: All authors
Corresponding author: Kemi M. Doll, MD, Division of Gynecologic Oncology,
University of North Carolina at Chapel Hill, Physicians Office Bldg, 101
ManningDr, Campus Box 7572, Chapel Hill, NC27599; e-mail: kmdoll@med.
unc.edu.
References
1. Freeman JD, Kadiyala S, Bell JF, et al: The causal effect of health insurance on
utilization and outcomes in adults: A systematic review of US studies. Med Care 46:
1023-1032, 2008
2. Medicaid: A Primer. Kaiser Commission on Medicaid and the Uninsured 2013.
https://kaiserfamilyfoundation.files.wordpress.com/2010/06/7334-05.pdf
3. Finkelstein A, Taubman S, Wright B, et al: The Oregon health insurance experi-
ment: Evidence from the first year. Q J Econ 127:1057-1106, 2012
4. Sommers BD, Baicker K, Epstein AM: Mortality and access to care among adults
after state Medicaid expansions. N Engl J Med 367:1025-1034, 2012
5. Walker GV, Grant SR, Guadagnolo BA, et al: Disparities in stage at diagnosis,
treatment, and survival in nonelderly adult patients with cancer according to in-
surance status. J Clin Oncol 32:3118-3125, 2014
6. Ku L, Bruen B, Steinmetz E, et al: The Economic and Employment Costs of
Not Expanding Medicaid in North Carolina: A County-Level Analysis. Wash-
ington, DC, Center for Health Policy Research The George Washington Uni-
versity, 2014
7. University of North Carolina Integrated Cancer Information and Surveillance
System Center. ICISS data resources. http://iciss.unc.edu/data.php
8. US Department of Agriculture Economic Research Service: Rural-urban contin-
uum codes, 2013. www.ers.usda.gov/data-products/rural-urban-continuum-codes/
documentation.aspx
9. Barakat RR, Markman M, Randall M: Principles and Practice of Gynecologic
Oncology (ed 5). Philadelphia, PA, Wolters Kluwer Health/Lippincott Williams &
Wilkins, 2009
10. Phelan JC, Link BG, Tehranifar P: Social conditions as fundamental causes of
health inequalities: Theory, evidence, and policy implications. J Health Soc Behav 51:
S28-S40, 2010 (suppl)
11. Link BG, Phelan J: Social conditions as fundamental causes of disease. J Health
Soc Behav Spec No.:80-94, 1995
12. Tehranifar P, Neugut AI, Phelan JC, et al: Medical advances and racial/ethnic
disparities in cancer survival. Cancer Epidemiol Biomarkers Prev 18:2701-2708,
2009
13. North Carolina Health and Human Services; Chronic Disease and Injury Section:
Breast and Cervical Cancer Control Program, 2016. http://bcccp.ncdhhs.gov
14. Howlader N, Noone AM, KrapchoM, et al: SEERCancer Statistics Review, 1975-
2011, National Cancer Institute, 2014. http://seer.cancer.gov/csr/1975_2011
15. Burke WM, Orr J, Leitao M, et al: Endometrial cancer: A review and current
management strategies: Part I. Gynecol Oncol 134:385-392, 2014 [Erratum:
Gynecol Oncol 135:625, 2014]
16. Long B, Liu FW, Bristow RE: Disparities in uterine cancer epidemiology, treat-
ment, and survival among African Americans in the United States. Gynecol Oncol
130:652-659, 2013
17. Cote ML, Ruterbusch JJ, Olson SH, et al: The growing burden of endometrial
cancer: A major racial disparity affecting black women. Cancer Epidemiol Biomarkers
Prev 24:1407-1415, 2015
18. Doll KM, Puliaev R, Chor J, et al: Detection of gynecologic cancers in in-
digent women in an urban inner-city hospital. Int J Gynecol Cancer 22:
1113-1117, 2012
19. Robbins AS, Han X,Ward EM, et al: Association between the Affordable Care Act
dependent coverage expansion and cervical cancer stage and treatment in young
women. JAMA 314:2189-2191, 2015
20. Garfield R, Damico A, Stephens J, et al: The Coverage Gap: Uninsured Poor
Adults in States That Do Not Expand Medicaid - An Update. Menlo Park, CA, Kaiser
Family Foundation, 2015
21. Glied S,Ma S: How states stand to gain or lose federal funds by opting in or out of
the Medicaid expansion. Issue Brief (Commonw Fund) 32:1-12, 2013
22. Hershman DL, Wright JD: Comparative effectiveness research in oncology
methodology: Observational data. J Clin Oncol 30:4215-4222, 2012
e730 Volume 12 / Issue 6 / June 2016 n Journal of Oncology Practice Copyright © 2016 by American Society of Clinical Oncology
Doll et al
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Clinical Benefits Associated With Medicaid Coverage Before Diagnosis of Gynecologic Cancers
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst =My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jop.ascopubs.org/site/misc/ifc.xhtml.
Kemi M. Doll
No relationship to disclose
Ethan M. Basch
No relationship to disclose
Ke Meng
No relationship to disclose
Emma L. Barber
No relationship to disclose
Paola A. Gehrig
No relationship to disclose
Wendy R. Brewster
No relationship to disclose
Anne-Marie Meyer
No relationship to disclose
Copyright © 2016 by American Society of Clinical Oncology Volume 12 / Issue 6 / June 2016 n jop.ascopubs.org e731
Medicaid Enrollment and Gynecologic Cancers
Appendix
2003–2008 NCCCR
gynecologic cancer cases
(N = 13,845)
Diagnosed alive
(n = 13,647)
ICD-0-3 code classification
of invasive malignancy
(n = 13,010)
Age ≥ 18 years
(n = 12,973)
Cervical, uterine, ovarian, or
vulvar/vaginal cancer site
(n = 12,791)
Age < 65 years
(n = 7,455)
Any Medicaid coverage
during study period
(n = 1,884)
Met Medicaid enrollment
criteria for study
(n = 963)
No documented disability
(n = 822)
Age < 65 years with exclusive
Medicaid coverage either before or
before and after cancer diagnosis
(n = 782)
Benign, in situ, or borderline ICD-0-3 code
(n = 637) excluded 
Age < 18 excluded
(n = 37) excluded
Gestational trophoblastic disease or other
unspecified gynecologic malignancy
(n = 182) excluded 
Age ≥ 65 years
(n = 5,336) excluded
No Medicaid enrollment flag
during study period
(n = 5,571) excluded
Additional insurance exclusions*
(n = 921) 
Enrollment based on primary disability
(n = 141) excluded 
Diagnosed at death or autopsy
(n = 198) excluded 
Other or missing race category
(n = 40)
FIG A1. Study population. ICD-O-3, International Classification of Diseases for Oncology, Third Edition; NCCCR, North Carolina Central Cancer Registry.
(*) Exclusions:, 6months of pre-diagnosis assessment time for enrollment (n = 146), lack of anyMedicaid enrollment prior to either study outcome (n = 655),
and additional enrollment in Medicare and/or private payer health insurance during the study period (n = 120).
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Table A1. ICD-O-3 Cancer Site Codes
Disease Site ICD-O-3 Code Description
Cervix C53.0 Endocervix
C53.1 Exocervix
C53.8 Overlapping lesion of cervix uteri
C53.9 Cervix uteri
Uterus C54.0 Isthmus uteri
C54.1 Endometrium
C54.3 Myometrium
C54.8 Fundus uteri
C54.9 Overlapping lesion of corpus uteri
C54.9 Corpus uteri
C55.9 Uterus, NOS
Ovary C56.9 Ovary
C57.0 Fallopian tubes/adnexa
C57.1 Broad ligament
C57.2 Round ligament
C57.3 Parametrium
C57.4 Uterine adnexa
C57.5 Other female genital organs
C57.8 Overlapping female genital organs
C57.9 Female genital tract, NOS
Vulva C51.0 Labium majus
C51.2 Labium minus
C51.8 Overlapping lesion of vulva
C51.9 Vulva, NOS
Vagina C52.9 Vagina, NOS
Abbreviations: ICD-O-3, International Classification of Diseases for Oncology,
Third Edition; NOS, not otherwise specified.
Table A2. Mortality After Gynecologic Cancer Diagnosis by Timing of Medicaid Enrollment, 2003 to 2008
Cancer Site* Prediagnosis Medicaid Coverage
Model 1 (without stage),
HR (95% CI) P
Model 2 (with stage),
HR (95% CI)
All sites No 1.28 (0.99 to 1.65) .06 1.19 (0.92 to 1.53)
Cervix No 1.26 (0.85 to 1.87) .26 1.32 (0.88 to 1.99)
Uterus No 1.46 (0.84 to 2.52) .17 1.20 (0.69 to 2.09)
Ovary No 1.19 (0.77 to 1.84) .42 1.13 (0.73 to 1.74)
Vulva/vagina No 1.23 (0.35 to 4.36) .75 1.46 (0.35 to 6.19)
Abbreviation: HR, hazard ratio.
*Number of deaths in each group: all sites (n = 177), cervix (n = 98), uterus (n = 52), ovary (n = 82), vulva/vagina (n = 10).
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